cjc-1295 hair growth: Frequently asked questions

CJC-1295 stacks well with CJC1295 Ipamorelin (a GHRP that further amplifies GH pulses) or MK 677 (a growth hormone secretagogue receptor agonist). When stacking, inject CJC-1295 first, wait 15–20 minutes, then administer the GHRP or MK-677. This sequential timing creates a larger, longer GH pulse than simultaneous injection. Do not combine with exogenous thyroid hormone or high-dose corticosteroids, both of which suppress GH secretion and negate CJC-1295's effect.

Hair follicle response to IGF-1 requires 10–16 weeks because you're extending anagen phase. Not reversing miniaturisation overnight. Visible density improvement from CJC-1295 appears when telogen (resting) follicles re-enter anagen and new growth reaches 1–2cm length, which takes 12–14 weeks minimum. If you're past week 16 with no improvement, verify your reconstitution accuracy, confirm you're dosing pre-sleep (not midday), and check baseline IGF-1 levels. Some individuals have IGF-1 receptor polymorphisms that reduce follicle responsiveness regardless of plasma concentration.

Administer the dose as soon as you remember if it's still within 12 hours of your intended time. The circadian benefit is reduced but not eliminated. If more than 12 hours have passed and it's now midday or afternoon, skip that dose entirely and resume your normal schedule with the next injection. Midday dosing when cortisol is elevated will produce minimal GH response and may cause insulin resistance without delivering follicle benefit. Missing one dose in a twice-weekly protocol means a 72-hour gap instead of 48 hours. IGF-1 will dip slightly but won't drop below baseline if you've been consistent for 4+ weeks.

Not necessarily fabricated, but likely confounded by concurrent interventions or placebo effect. Many users combine CJC-1295 with minoxidil, finasteride, dermarolling, or other proven modalities. Attributing the observed regrowth to the peptide rather than the evidence-based treatments is a classic correlation-causation error. Hair growth also has a natural cyclical variability, with spontaneous anagen reactivation occurring in some follicles independent of any intervention. Without controlled conditions. Baseline follicular counts, blinded assessment, and isolation of variables. Anecdotal reports are scientifically uninformative.

CJC-1295 does not promote hair loss and will not worsen androgenic alopecia. Its mechanism does not elevate DHT or alter androgen receptor sensitivity. If you're using it for validated purposes like muscle preservation during a caloric deficit, improved recovery from training, or management of age-related GH decline, it's safe to continue without concern for follicular health. Just don't expect it to function as a hair restoration agent alongside those benefits.

Continue only if you're using it for validated endpoints like body composition or GH deficiency management. If hair regrowth was your sole goal, redirect to compounds with documented follicular activity. Topical minoxidil (which directly increases VEGF and prolongs anagen), oral finasteride or dutasteride (which inhibit 5α-reductase and reduce DHT), or research peptides like GHK-Cu that demonstrate Wnt pathway activation in dermal papilla cultures. CJC-1295 won't harm your hair, but it won't restore it either. Continuing it solely for that purpose wastes both time and biological opportunity during a critical intervention window.